Oral oncology最新文献_第5页

Establishment of novel stable human sinonasal NUT carcinoma cell lines 稳定的新型人鼻窦NUT癌细胞系的建立。

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2026-01-03 DOI: 10.1016/j.oraloncology.2025.107828

Yoko Takahashi , Diana Bell , Arnoldo Corona , Shirely Y Su , Renata Ferrarotto , Brandon Gunn , Franco DeMonte , Shaan Raza , Ehab Y Hanna

Purpose

NUT carcinoma is a rare and aggressive malignancy defined by NUTM1 gene rearrangements, with no standard treatment approaches and limited preclinical models, especially for tumors arising in the sinonasal tract. We aimed to establish and characterize novel, stable sinonasal NUT carcinoma cell lines derived from the primary disease site to contribute to therapeutic development.

Experimental design

Tumor specimens from a sinonasal NUT carcinoma patient were cultured to establish two cell lines, MDA-NUT87 and MDA-NUT88. Cytogenetic analysis, immunohistochemistry, RT-PCR, and Sanger sequencing confirmed the presence of the BRD4::NUTM1 fusion. Sensitivity to a BET inhibitor, OTX-015, was assessed via dose–response assays. In vivo tumorigenicity was evaluated using subcutaneous xenografts in nude mice.

Results

MDA-NUT87 and MDA-NUT88 maintained stable morphology and harbored the characteristic t(15;19) translocation and BRD4::NUTM1 (exon 11: exon 2) fusion. The cells expressed nuclear NUT protein and responded to OTX-015 with IC₅₀ values in the low nanomolar range. Tumorigenicity was observed in vivo, albeit with modest efficiency, suggesting a contributing role of the tumor microenvironment in disease progression.

Conclusions

MDA-NUT87 and MDA-NUT88 are the first stable human sinonasal NUT carcinoma cell lines established from the primary tumor site. They preserve the hallmark genetic and phenotypic characteristics of NUT carcinoma and show sensitivity to BET inhibition. These models represent valuable tools for mechanistic studies and high-throughput drug screening in sinonasal NUT carcinoma.

目的：NUT癌是一种罕见的侵袭性恶性肿瘤，由NUTM1基因重排定义，没有标准的治疗方法和有限的临床前模型，特别是发生在鼻窦的肿瘤。我们的目的是建立和表征来自原发疾病部位的新型、稳定的鼻窦NUT癌细胞系，以促进治疗发展。实验设计：培养1例鼻窦NUT癌患者肿瘤标本，建立MDA-NUT87和MDA-NUT88两个细胞系。细胞遗传学分析、免疫组织化学、RT-PCR和Sanger测序证实了BRD4::NUTM1融合的存在。通过剂量-反应试验评估对BET抑制剂OTX-015的敏感性。用裸鼠皮下异种移植物评估体内致瘤性。结果：MDA-NUT87和MDA-NUT88形态保持稳定，具有t（15;19）易位和BRD4::NUTM1（外显子11：外显子2）融合的特征。细胞表达核NUT蛋白，对OTX-015有反应，IC50值在低纳摩尔范围内。在体内观察到致瘤性，尽管效率不高，但表明肿瘤微环境在疾病进展中起着重要作用。结论：MDA-NUT87和MDA-NUT88是第一个从原发肿瘤部位建立的稳定的人鼻窦NUT癌细胞系。它们保留了NUT癌的标志性遗传和表型特征，并表现出对BET抑制的敏感性。这些模型为鼻窦NUT癌的机制研究和高通量药物筛选提供了有价值的工具。

{"title":"Establishment of novel stable human sinonasal NUT carcinoma cell lines","authors":"Yoko Takahashi , Diana Bell , Arnoldo Corona , Shirely Y Su , Renata Ferrarotto , Brandon Gunn , Franco DeMonte , Shaan Raza , Ehab Y Hanna","doi":"10.1016/j.oraloncology.2025.107828","DOIUrl":"10.1016/j.oraloncology.2025.107828","url":null,"abstract":"<div><h3>Purpose</h3><div>NUT carcinoma is a rare and aggressive malignancy defined by <em>NUTM1</em> gene rearrangements, with no standard treatment approaches and limited preclinical models, especially for tumors arising in the sinonasal tract. We aimed to establish and characterize novel, stable sinonasal NUT carcinoma cell lines derived from the primary disease site to contribute to therapeutic development.</div></div><div><h3>Experimental design</h3><div>Tumor specimens from a sinonasal NUT carcinoma patient were cultured to establish two cell lines, MDA-NUT87 and MDA-NUT88. Cytogenetic analysis, immunohistochemistry, RT-PCR, and Sanger sequencing confirmed the presence of the <em>BRD4::NUTM1</em> fusion. Sensitivity to a BET inhibitor, OTX-015, was assessed via dose–response assays. In vivo tumorigenicity was evaluated using subcutaneous xenografts in nude mice.</div></div><div><h3>Results</h3><div>MDA-NUT87 and MDA-NUT88 maintained stable morphology and harbored the characteristic t(15;19) translocation and <em>BRD4::NUTM1</em> (exon 11: exon 2) fusion. The cells expressed nuclear NUT protein and responded to OTX-015 with IC<sub>50</sub> values in the low nanomolar range. Tumorigenicity was observed in vivo, albeit with modest efficiency, suggesting a contributing role of the tumor microenvironment in disease progression.</div></div><div><h3>Conclusions</h3><div>MDA-NUT87 and MDA-NUT88 are the first stable human sinonasal NUT carcinoma cell lines established from the primary tumor site. They preserve the hallmark genetic and phenotypic characteristics of NUT carcinoma and show sensitivity to BET inhibition. These models represent valuable tools for mechanistic studies and high-throughput drug screening in sinonasal NUT carcinoma.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107828"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis 丹麦头颈癌趋势：全国40年数据分析

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2025-12-30 DOI: 10.1016/j.oraloncology.2025.107843

Kathrine K. Jakobsen , Jacob H. Rasmussen , Jacob Melchiors , Tina K. Agander , Christian von Buchwald , Christian Grønhøj

Background and purpose

Head and neck cancers (HNCs) encompass various malignancies with variation in anatomical site, histology, and survival outcomes. This study aims to describe HNC incidence and survival trends in Denmark from 1980 to 2021.

Patients/material and methods

This retrospective, cohort study used data from the Danish Cancer Registry and the Central Population Register to include all HNC cases in the upper aerodigestive tract from 1980 to 2021. Incidence rates were age-adjusted and survival analyzed as relative survival rates compared to the general population. Average Annual Percent Change (AAPC) in incidence was calculated using linear regression models.

Results

A total of 36,626 HNC cases were included. The age-adjusted incidence rate (AAIR) increased significantly from 7.1 in 1980 to 12.5 per 100,000 in 2021. From 2015 to 2021, oropharyngeal cancer was the most common HNC. Further, oropharyngeal cancer demonstrated the highest 5-year relative survival of 70.1 % [95 % CI: 67.9–72.4]. Hypopharyngeal cancer had the lowest survival (26.8 % [95 % CI: 25.1 to 28.7]). Overall, the 5-year relative survival improved during the study period from 46.9 % [95 % CI: 44.7–49.2] in 1980–1984 to 65.2 % [95 % CI: 63.8 to 66.6] in 2015–2019.

Interpretation

Our study showed a continued increase in incidence for HNC alongside an improvement in survival. The survival varied notably across different tumor subsite. Continued research is essential to address these variations and improve outcomes across cancer subsites. Exploring opportunities for treatment de-escalation to mitigate the toxicity associated with current therapies is essential to optimizing long-term quality of life for survivors.

背景和目的：头颈癌（HNCs）包括各种不同的恶性肿瘤，在解剖部位、组织学和生存结果上都有差异。本研究旨在描述1980年至2021年丹麦HNC发病率和生存趋势。患者/材料和方法：这项回顾性队列研究使用了丹麦癌症登记处和中央人口登记处的数据，包括1980年至2021年期间所有上气消化道HNC病例。对发病率进行年龄调整，并将生存率作为与一般人群相比的相对生存率进行分析。采用线性回归模型计算发病率的年均百分率变化（AAPC）。结果：共纳入HNC病例36626例。年龄调整后的发病率（AAIR）从1980年的7.1 / 10万显著增加到2021年的12.5 / 10万。2015 - 2021年，口咽癌是最常见的HNC。此外，口咽癌的5年相对生存率最高，为70.1% [95% CI: 67.9-72.4]。下咽癌的生存率最低（26.8% [95% CI: 25.1 ~ 28.7]）。总体而言，研究期间的5年相对生存率从1980-1984年的46.9% [95% CI: 44.7-49.2]提高到2015-2019年的65.2% [95% CI: 63.8 - 66.6]。解释：我们的研究显示，HNC的发病率在持续增加的同时，生存率也在提高。不同肿瘤亚区生存率差异显著。持续的研究对于解决这些差异和改善癌症亚位点的结果至关重要。探索治疗降级的机会，以减轻与当前治疗相关的毒性，对于优化幸存者的长期生活质量至关重要。

{"title":"Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis","authors":"Kathrine K. Jakobsen , Jacob H. Rasmussen , Jacob Melchiors , Tina K. Agander , Christian von Buchwald , Christian Grønhøj","doi":"10.1016/j.oraloncology.2025.107843","DOIUrl":"10.1016/j.oraloncology.2025.107843","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Head and neck cancers (HNCs) encompass various malignancies with variation in anatomical site, histology, and survival outcomes. This study aims to describe HNC incidence and survival trends in Denmark from 1980 to 2021.</div></div><div><h3>Patients/material and methods</h3><div>This retrospective, cohort study used data from the Danish Cancer Registry and the Central Population Register to include all HNC cases in the upper aerodigestive tract from 1980 to 2021. Incidence rates were age-adjusted and survival analyzed as relative survival rates compared to the general population. Average Annual Percent Change (AAPC) in incidence was calculated using linear regression models.</div></div><div><h3>Results</h3><div>A total of 36,626 HNC cases were included. The age-adjusted incidence rate (AAIR) increased significantly from 7.1 in 1980 to 12.5 per 100,000 in 2021. From 2015 to 2021, oropharyngeal cancer was the most common HNC. Further, oropharyngeal cancer demonstrated the highest 5-year relative survival of 70.1 % [95 % CI: 67.9–72.4]. Hypopharyngeal cancer had the lowest survival (26.8 % [95 % CI: 25.1 to 28.7]). Overall, the 5-year relative survival improved during the study period from 46.9 % [95 % CI: 44.7–49.2] in 1980–1984 to 65.2 % [95 % CI: 63.8 to 66.6] in 2015–2019.</div></div><div><h3>Interpretation</h3><div>Our study showed a continued increase in incidence for HNC alongside an improvement in survival. The survival varied notably across different tumor subsite. Continued research is essential to address these variations and improve outcomes across cancer subsites. Exploring opportunities for treatment de-escalation to mitigate the toxicity associated with current therapies is essential to optimizing long-term quality of life for survivors.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107843"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Jaw-in-a-day (JIAD) for malignant indications: A systematic review 每日一颌（JIAD）治疗恶性适应症：一项系统综述

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.oraloncology.2025.107823

Jessica Trac , Rashi Ramchandani , Pallavi Dutta , Leba Sarkis , Robert Calvisi , Noémie Villemure-Poliquin , Joel Davies , Eszter Somogyi-Ganss , Nick Blanas , Karl Cuddy , Danny Enepekides , Kevin Higgins , Justine Philteos , Antoine Eskander

Introduction

Jaw-in-a-day (JIAD) achieves resection, maxillofacial reconstruction and immediate dental rehabilitation. While increasingly used, evidence in oncologic populations remains limited. Our objective was to review JIAD in patients with head and neck cancer (HNC) and its outcomes.

Methods

Our systematic review was conducted following a predefined protocol (PROSPERO CRD420251043510). Our search strategy was executed on MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL from January 2013 to October 2025. Studies with HNC patients of all ages who underwent JIAD were included. The Methodological Index for Non-Randomized Studies (MINORS) was used for risk of bias assessment.

Results

Nine studies were included with 57 patients. Common tumour characteristics included mandibular location (n = 31; 54.4 %) and squamous cell carcinoma pathology (n = 37; 64.9 %). A fibular free flap was used in all cases (n = 57; 100 %). Majority underwent adjuvant therapy (n = 36; 63.2 %). Prosthesis survival was reported in 6 studies (n = 25/32; 78.1 %) with follow-up periods ranging from 5 to 52 months. Prosthesis removal was commonly due to osteoradionecrosis (ORN) (n = 6; 10.5 %). All irradiated implants had successful early osseointegration (n = 99; 100 %). Delayed implant failure was reported in 4 patients (n = 4/36; 11.1 %) with 11 implants in radiotherapy field (n = 11/99; 11.1 %).

Conclusion

JIAD for HNC patients can have high success in majority of select patients/defects. Although early osseointegration rates were high, oncologic patients receiving adjuvant radiation may remain at elevated risk for ORN-associated prosthesis failure. As such, the risks and benefits of JIAD should be carefully reviewed with the patient, and cancer staging should also be considered.

JIAD技术实现了颌面切除、颌面重建和口腔即刻康复。虽然越来越多地使用，但在肿瘤人群中的证据仍然有限。我们的目的是回顾头颈癌（HNC）患者的JIAD及其预后。方法按照预先确定的方案（PROSPERO CRD420251043510）进行系统评价。我们的搜索策略从2013年1月到2025年10月在MEDLINE， Embase， CENTRAL， Web of Science和CINAHL上执行。研究纳入了所有年龄的接受JIAD治疗的HNC患者。采用非随机研究方法学指数进行偏倚风险评估。结果纳入9项研究，共57例患者。常见的肿瘤特征包括下颌位置（n = 31, 54.4%）和鳞状细胞癌病理（n = 37, 64.9%）。所有病例均采用腓骨游离皮瓣（n = 57; 100%）。大多数接受了辅助治疗（n = 36; 63.2%）。6项研究（n = 25/32; 78.1%）报告了假体的存活，随访时间为5至52个月。假体切除通常是由于骨放射性坏死（ORN）（n = 6; 10.5%）。所有辐照种植体早期骨整合成功（n = 99; 100%）。4例患者（n = 4/36; 11.1%）报告了延迟种植失败，11例患者在放疗现场种植（n = 11/99; 11.1%）。结论jiad治疗HNC患者可获得较高的成功率。尽管早期骨整合率很高，但接受辅助放疗的肿瘤患者可能仍然存在orn相关假体失败的高风险。因此，JIAD的风险和益处应与患者一起仔细评估，也应考虑癌症分期。

{"title":"Jaw-in-a-day (JIAD) for malignant indications: A systematic review","authors":"Jessica Trac , Rashi Ramchandani , Pallavi Dutta , Leba Sarkis , Robert Calvisi , Noémie Villemure-Poliquin , Joel Davies , Eszter Somogyi-Ganss , Nick Blanas , Karl Cuddy , Danny Enepekides , Kevin Higgins , Justine Philteos , Antoine Eskander","doi":"10.1016/j.oraloncology.2025.107823","DOIUrl":"10.1016/j.oraloncology.2025.107823","url":null,"abstract":"<div><h3>Introduction</h3><div>Jaw-in-a-day (JIAD) achieves resection, maxillofacial reconstruction and immediate dental rehabilitation. While increasingly used, evidence in oncologic populations remains limited. Our objective was to review JIAD in patients with head and neck cancer (HNC) and its outcomes.</div></div><div><h3>Methods</h3><div>Our systematic review was conducted following a predefined protocol (PROSPERO CRD420251043510). Our search strategy was executed on MEDLINE, Embase, CENTRAL, Web of Science, and CINAHL from January 2013 to October 2025. Studies with HNC patients of all ages who underwent JIAD were included. The Methodological Index for Non-Randomized Studies (MINORS) was used for risk of bias assessment.</div></div><div><h3>Results</h3><div>Nine studies were included with 57 patients. Common tumour characteristics included mandibular location (n = 31; 54.4 %) and squamous cell carcinoma pathology (n = 37; 64.9 %). A fibular free flap was used in all cases (n = 57; 100 %). Majority underwent adjuvant therapy (n = 36; 63.2 %). Prosthesis survival was reported in 6 studies (n = 25/32; 78.1 %) with follow-up periods ranging from 5 to 52 months. Prosthesis removal was commonly due to osteoradionecrosis (ORN) (n = 6; 10.5 %). All irradiated implants had successful early osseointegration (n = 99; 100 %). Delayed implant failure was reported in 4 patients (n = 4/36; 11.1 %) with 11 implants in radiotherapy field (n = 11/99; 11.1 %).</div></div><div><h3>Conclusion</h3><div>JIAD for HNC patients can have high success in majority of select patients/defects. Although early osseointegration rates were high, oncologic patients receiving adjuvant radiation may remain at elevated risk for ORN-associated prosthesis failure. As such, the risks and benefits of JIAD should be carefully reviewed with the patient, and cancer staging should also be considered.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107823"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of a risk nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma 预测甲状腺乳头状微癌中央淋巴结转移的风险图的建立和验证

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2025-12-31 DOI: 10.1016/j.oraloncology.2025.107842

Weidong Zhang, Xianjiang Wu, Yingchun Wang, Qi Le, Yue Xie, Kejie Yu

Background

The global incidence of papillary thyroid microcarcinoma (PTMC) continues to rise, and the optimal management strategy remains controversial due to its generally favorable prognosis. Central lymph node metastasis (CLNM) is an important predictor of recurrence and survival and therefore plays a critical role in guiding therapeutic decision-making. This study aimed to develop and validate a nomogram to preoperatively predict the risk of CLNM in PTMC patients.

Methods

Patients from ward A (n = 877) were assigned to the training cohort, and those from ward B (n = 637) formed the validation cohort. Clinical characteristics and ultrasonographic variables were evaluated. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of CLNM, which were subsequently incorporated into a predictive nomogram. Model performance was assessed using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA).

Results

Univariate analysis identified gender, age, maximum tumor diameter (MTD), multifocality, calcification and capsule status as significantly associated with CLNM (P < 0.05). Multivariate logistic regression analysis revealed gender, age, MTD, multifocality, and capsule status as independent predictors. The nomogram demonstrated good discriminative ability, with an area under the curve (AUC) of 0.724 in the training cohort and 0.708 in the validation cohort. Calibration curves showed excellent agreement between predicted and observed outcomes, and DCA confirmed favorable clinical utility.

Conclusion

We successfully developed and validated a clinically applicable nomogram that integrates preoperative clinical and ultrasonographic features to predict CLNM in PTMC patients. This model may assist clinicians in tailoring surgical strategies and optimizing individualized management.

背景：甲状腺乳头状微癌（PTMC）的全球发病率持续上升，由于其普遍预后良好，最佳治疗策略仍存在争议。中央淋巴结转移（CLNM）是复发和生存的重要预测因素，因此在指导治疗决策中起着关键作用。本研究旨在开发和验证一种nomogram方法，用于术前预测PTMC患者发生CLNM的风险。方法将A病区877例患者纳入训练队列，B病区637例患者纳入验证队列。评估临床特征和超声指标。进行单变量和多变量逻辑回归分析以确定CLNM的独立预测因子，随后将其纳入预测nomogram。采用受试者工作特征（ROC）分析、校准曲线和决策曲线分析（DCA）评估模型的性能。结果单因素分析发现，性别、年龄、最大肿瘤直径（MTD）、多灶性、钙化和被囊状态与CLNM显著相关（P < 0.05）。多因素logistic回归分析显示，性别、年龄、MTD、多病灶和胶囊状态是独立的预测因素。nomogram具有较好的判别能力，训练组和验证组的曲线下面积（AUC）分别为0.724和0.708。校准曲线显示预测结果和观察结果非常吻合，DCA证实了良好的临床应用。结论我们成功开发并验证了一种临床适用的nomogram，该nomogram结合了术前临床和超声特征来预测PTMC患者的CLNM。该模型可以帮助临床医生定制手术策略和优化个性化管理。

{"title":"Development and validation of a risk nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma","authors":"Weidong Zhang, Xianjiang Wu, Yingchun Wang, Qi Le, Yue Xie, Kejie Yu","doi":"10.1016/j.oraloncology.2025.107842","DOIUrl":"10.1016/j.oraloncology.2025.107842","url":null,"abstract":"<div><h3>Background</h3><div>The global incidence of papillary thyroid microcarcinoma (PTMC) continues to rise, and the optimal management strategy remains controversial due to its generally favorable prognosis. Central lymph node metastasis (CLNM) is an important predictor of recurrence and survival and therefore plays a critical role in guiding therapeutic decision-making. This study aimed to develop and validate a nomogram to preoperatively predict the risk of CLNM in PTMC patients.</div></div><div><h3>Methods</h3><div>Patients from ward A (n = 877) were assigned to the training cohort, and those from ward B (n = 637) formed the validation cohort. Clinical characteristics and ultrasonographic variables were evaluated. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of CLNM, which were subsequently incorporated into a predictive nomogram. Model performance was assessed using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA).</div></div><div><h3>Results</h3><div>Univariate analysis identified gender, age, maximum tumor diameter (MTD), multifocality, calcification and capsule status as significantly associated with CLNM (P < 0.05). Multivariate logistic regression analysis revealed gender, age, MTD, multifocality, and capsule status as independent predictors. The nomogram demonstrated good discriminative ability, with an area under the curve (AUC) of 0.724 in the training cohort and 0.708 in the validation cohort. Calibration curves showed excellent agreement between predicted and observed outcomes, and DCA confirmed favorable clinical utility.</div></div><div><h3>Conclusion</h3><div>We successfully developed and validated a clinically applicable nomogram that integrates preoperative clinical and ultrasonographic features to predict CLNM in PTMC patients. This model may assist clinicians in tailoring surgical strategies and optimizing individualized management.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107842"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy 同种异体骨髓移植后头颈部鳞状细胞癌：临床特征、基因组改变和姑息性化疗的有限疗效

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2025-12-26 DOI: 10.1016/j.oraloncology.2025.107827

Song Ee Park , Sook-Hee Hong , Jun-Ook Park , Sang-Yeon Kim , Dong-Il Sun , Yeon-Sil Kim , Won-Jong Park , Meejeong Kim , Youn Soo Lee , Jin Hyoung Kang

Background

Head and neck squamous cell carcinoma (HNSCC) is an uncommon but serious late complication after allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated clinical features, molecular alterations, and outcomes of post-HSCT HNSCC, with emphasis on recurrent disease.

Methods

Thirty-four patients diagnosed with HNSCC after allogeneic HSCT between January 2009 and May 2025 were retrospectively analyzed. Clinical characteristics, transplantation history, tumor location, HPV status, treatment, PD-L1 expression, and survival were assessed. Whole-exome sequencing (WES) was performed.

Results

Median age at HNSCC diagnosis was 53 years (range, 6–75), with 73.5 % male. Leukemia was the most common primary malignancy (70.5 %). The oral tongue was the most frequent site (55.9 %), followed by buccal mucosa (23.5 %). Median interval from HSCT to HNSCC was 86.8 months (95 % CI, 72.4–104.7), and median follow-up was 54.8 months (95 % CI, 24.1–85.4). Chronic GVHD was associated with inferior disease-free survival (44.4 months vs. not reached; HR 3.98; 95 % CI, 1.05–15.04; P = 0.044). Among four patients with recurrent HNSCC receiving palliative chemotherapy, median progression-free survival was only 0.7 months (95 % CI, 0.669–0.865). One patient with high PD-L1 expression received pembrolizumab but derived limited benefit. WES identified recurrent TP53 mutations and alterations in PIK3R2, KIT, EGFR, and PIK3CA. All tumors were microsatellite stable with low tumor mutational burden.

Conclusions

HNSCC after HSCT typically develops after prolonged latency and shows favorable outcomes with curative therapy. However, recurrence is marked by rapid progression and poor systemic treatment response, underscoring the prognostic relevance of chronic GVHD and the need for novel therapeutic strategies.

背景头颈部鳞状细胞癌（HNSCC）是异体造血干细胞移植（HSCT）后罕见但严重的晚期并发症。我们评估了hsct后HNSCC的临床特征、分子改变和结局，重点是复发性疾病。方法回顾性分析2009年1月至2025年5月间34例同种异体造血干细胞移植后诊断为HNSCC的患者。评估临床特征、移植史、肿瘤位置、HPV状态、治疗、PD-L1表达和生存率。进行全外显子组测序（WES）。结果HNSCC诊断的中位年龄为53岁（范围6-75岁），其中73.5%为男性。白血病是最常见的原发恶性肿瘤（70.5%）。口腔舌头是最常见的部位（55.9%），其次是颊粘膜（23.5%）。从HSCT到HNSCC的中位时间间隔为86.8个月（95% CI, 72.4-104.7），中位随访时间为54.8个月（95% CI, 24.1-85.4）。慢性GVHD与较差的无病生存期相关（44.4个月vs.未达到；HR 3.98; 95% CI, 1.05-15.04; P = 0.044）。在接受姑息性化疗的4例复发性鳞状细胞癌患者中，中位无进展生存期仅为0.7个月（95% CI, 0.669-0.865）。一名PD-L1高表达的患者接受了派姆单抗治疗，但获益有限。WES发现复发性TP53突变和PIK3R2、KIT、EGFR和PIK3CA的改变。所有肿瘤微卫星稳定，肿瘤突变负荷低。结论HSCT后shnscc通常在较长潜伏期后发生，经治疗后预后良好。然而，复发的特点是进展迅速和全身治疗反应差，这强调了慢性GVHD的预后相关性和对新治疗策略的需求。

{"title":"Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy","authors":"Song Ee Park , Sook-Hee Hong , Jun-Ook Park , Sang-Yeon Kim , Dong-Il Sun , Yeon-Sil Kim , Won-Jong Park , Meejeong Kim , Youn Soo Lee , Jin Hyoung Kang","doi":"10.1016/j.oraloncology.2025.107827","DOIUrl":"10.1016/j.oraloncology.2025.107827","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck squamous cell carcinoma (HNSCC) is an uncommon but serious late complication after allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated clinical features, molecular alterations, and outcomes of post-HSCT HNSCC, with emphasis on recurrent disease.</div></div><div><h3>Methods</h3><div>Thirty-four patients diagnosed with HNSCC after allogeneic HSCT between January 2009 and May 2025 were retrospectively analyzed. Clinical characteristics, transplantation history, tumor location, HPV status, treatment, PD-L1 expression, and survival were assessed. Whole-exome sequencing (WES) was performed.</div></div><div><h3>Results</h3><div>Median age at HNSCC diagnosis was 53 years (range, 6–75), with 73.5 % male. Leukemia was the most common primary malignancy (70.5 %). The oral tongue was the most frequent site (55.9 %), followed by buccal mucosa (23.5 %). Median interval from HSCT to HNSCC was 86.8 months (95 % CI, 72.4–104.7), and median follow-up was 54.8 months (95 % CI, 24.1–85.4). Chronic GVHD was associated with inferior disease-free survival (44.4 months vs. not reached; HR 3.98; 95 % CI, 1.05–15.04; P = 0.044). Among four patients with recurrent HNSCC receiving palliative chemotherapy, median progression-free survival was only 0.7 months (95 % CI, 0.669–0.865). One patient with high PD-L1 expression received pembrolizumab but derived limited benefit. WES identified recurrent TP53 mutations and alterations in PIK3R2, KIT, EGFR, and PIK3CA. All tumors were microsatellite stable with low tumor mutational burden.</div></div><div><h3>Conclusions</h3><div>HNSCC after HSCT typically develops after prolonged latency and shows favorable outcomes with curative therapy. However, recurrence is marked by rapid progression and poor systemic treatment response, underscoring the prognostic relevance of chronic GVHD and the need for novel therapeutic strategies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107827"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From risk factors to clinical Decisions: Methodological Considerations in Predicting occult metastasis in papillary thyroid carcinoma 从危险因素到临床决策：预测甲状腺乳头状癌隐匿转移的方法学考虑

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2026-01-15 DOI: 10.1016/j.oraloncology.2026.107854

Weiqun Wang, Yaling Lou

引用次数: 0

Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma 基于正电子发射层析成像的肿瘤内空间多样性对鼻咽癌预后的影响

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2026-01-01 DOI: 10.1016/j.oraloncology.2025.107845

Shuxian Niu , Jianming Ding , Hanshen Chen , Zeyu Zhu , Xiyi Liao , Huiling Hong , Chuanben Chen , Jiyang Dong , Zhaodong Fei

Background

This study aimed to develop a radiomics-based framework for quantifying intratumoral heterogeneity (ITH) in nasopharyngeal carcinoma (NPC) using three-dimensional tumor subregions. The goal was to enhance conventional clinical risk stratification and investigate the biological basis of ITH.

Methods

This multicenter retrospective study included PET scans from 760 treatment-naïve NPC patients. Radiomics features were extracted from the whole tumor (WT), and the intratumoral spatial diversity score (ITSDS) was simultaneously quantified through subregion analysis. After a multi-step feature selection process, both WT and ITH models were developed. Finally, a nomogram was constructed by integrating ITSDS with clinical factors. All models were evaluated using the C-index, AUC, and calibration curves, and their performance was interpreted using SHAP. Additionally, the biological characteristics of the ITH model were analyzed using tissue proteomics.

Results

The training, internal validation, and external validation cohorts included 480, 235, and 45 patients, respectively. The ITH model showed superior C-indexes of 0.852, 0.792, and 0.757 compared to the clinical and WT models. The nomogram demonstrated the best prognostic value, with C-indexes of 0.864, 0.817, and 0.772 in the three cohorts, respectively. The nomogram effectively classified patients into risk groups for progression-free survival (P < 0.01). Tissue proteomic analysis revealed upregulated ciliary movement, a more complex tumor microenvironment, and impaired immune function in the high-ITH group.

Conclusion

The nomogram integrating ITSDS biomarkers with clinical factors improved risk stratification accuracy and created a clinically translatable framework for NPC. This approach potentially offers mechanistic insights into ITH and holds promise for advancing precision oncology.

本研究旨在建立一个基于放射组学的框架，利用三维肿瘤亚区来量化鼻咽癌（NPC）的肿瘤内异质性（ITH）。目的是加强常规临床风险分层和探讨ITH的生物学基础。方法本多中心回顾性研究包括760例treatment-naïve NPC患者的PET扫描。从整个肿瘤（WT）中提取放射组学特征，并通过分区域分析同时量化肿瘤内空间多样性评分（ITSDS）。经过多步特征选择过程，开发了WT和ITH模型。最后，将ITSDS与临床因素相结合，构建nomogram。使用c指数、AUC和校准曲线对所有模型进行评估，并使用SHAP对其性能进行解释。此外，利用组织蛋白质组学分析ITH模型的生物学特性。结果培训队列、内部验证队列和外部验证队列分别包括480例、235例和45例患者。与临床模型和WT模型相比，ITH模型的c指数分别为0.852、0.792和0.757。nomogram显示了最佳的预后价值，3个队列的c指数分别为0.864、0.817和0.772。nomogram无进展生存图（P < 0.01）有效地将患者分为危险组。组织蛋白质组学分析显示，高ith组纤毛运动上调，肿瘤微环境更复杂，免疫功能受损。结论结合ITSDS生物标志物与临床因素的nomogram风险分层方法提高了风险分层的准确性，为鼻咽癌的临床诊断提供了一个可翻译的框架。这种方法为ITH提供了潜在的机制见解，并有望推进精准肿瘤学。

{"title":"Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma","authors":"Shuxian Niu , Jianming Ding , Hanshen Chen , Zeyu Zhu , Xiyi Liao , Huiling Hong , Chuanben Chen , Jiyang Dong , Zhaodong Fei","doi":"10.1016/j.oraloncology.2025.107845","DOIUrl":"10.1016/j.oraloncology.2025.107845","url":null,"abstract":"<div><h3>Background</h3><div>This study aimed to develop a radiomics-based framework for quantifying intratumoral heterogeneity (ITH) in nasopharyngeal carcinoma (NPC) using three-dimensional tumor subregions. The goal was to enhance conventional clinical risk stratification and investigate the biological basis of ITH.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study included PET scans from 760 treatment-naïve NPC patients. Radiomics features were extracted from the whole tumor (WT), and the intratumoral spatial diversity score (ITSDS) was simultaneously quantified through subregion analysis. After a multi-step feature selection process, both WT and ITH models were developed. Finally, a nomogram was constructed by integrating ITSDS with clinical factors. All models were evaluated using the C-index, AUC, and calibration curves, and their performance was interpreted using SHAP. Additionally, the biological characteristics of the ITH model were analyzed using tissue proteomics.</div></div><div><h3>Results</h3><div>The training, internal validation, and external validation cohorts included 480, 235, and 45 patients, respectively. The ITH model showed superior C-indexes of 0.852, 0.792, and 0.757 compared to the clinical and WT models. The nomogram demonstrated the best prognostic value, with C-indexes of 0.864, 0.817, and 0.772 in the three cohorts, respectively. The nomogram effectively classified patients into risk groups for progression-free survival (P < 0.01). Tissue proteomic analysis revealed upregulated ciliary movement, a more complex tumor microenvironment, and impaired immune function in the high-ITH group.</div></div><div><h3>Conclusion</h3><div>The nomogram integrating ITSDS biomarkers with clinical factors improved risk stratification accuracy and created a clinically translatable framework for NPC. This approach potentially offers mechanistic insights into ITH and holds promise for advancing precision oncology.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107845"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma 基于集成学习的放射组学模型预测鼻咽癌放射诱导的颞叶损伤

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2025-12-26 DOI: 10.1016/j.oraloncology.2025.107841

Meng Zhang , Jian Song , Yiming Yuan , Xiujuan Cao

Purpose

To develop and validate a multimodal ensemble machine learning model integrating multi-sequence magnetic resonance imaging (MRI) radiomics, clinical characteristics, and hematological biomarkers for early prediction of Radiation-induced temporal lobe injury (RTLI) in Nasopharyngeal carcinoma (NPC) patients before radiotherapy.

Methods

A total of 161 NPC patients treated with intensity-modulated radiation therapy (IMRT) were retrospectively analyzed and randomly assigned to training (n = 113) and validation (n = 48) sets in a 7:3 ratio. Radiomic features were extracted from pretreatment T1WI, CE-T1WI, T2WI, and DWI, with features showing ICC > 0.75 retained. After SMOTE balancing, Elastic Net (EN) was used for feature selection to generate EN-scores, and Random Forest (RF) produced RF-scores. These, together with two SVM-based scores obtained from demographic and hematological biomarkers, were combined into an ensemble ERSS (EN–RF–SVM–SVM) model. Model performance was evaluated using ROC analysis, calibration, and decision curve analysis.

Results

The ERSS model demonstrated superior predictive performance compared with single-sequence, multi-sequence MRI integration models and LR model. The AUCs of the ERSS model were 0.957 in the training set and 0.968 in the validation set. Calibration curves showed excellent agreement between predicted and observed outcomes. DCA indicated that the ERSS model provided the highest net clinical benefit across a wide range of threshold probabilities compared with other models.

Conclusion

The ERSS multimodal ensemble learning model provides a highly accurate and clinically meaningful tool for early prediction of RTLI in NPC patients. By integrating multi-sequence MRI radiomics, hematological biomarkers, and clinical factors, the ERSS model enables individualized risk assessment and may assist in optimizing radiotherapy planning and follow-up strategies.

目的建立并验证融合多序列磁共振成像（MRI）放射组学、临床特征和血液学生物标志物的多模态集成机器学习模型，用于鼻咽癌（NPC）放疗前放射诱导颞叶损伤（RTLI）的早期预测。方法回顾性分析接受调强放疗（IMRT）治疗的161例鼻咽癌患者，按7:3的比例随机分为训练组（n = 113）和验证组（n = 48）。提取预处理T1WI、CE-T1WI、T2WI和DWI的放射学特征，保留ICC >； 0.75的特征。SMOTE平衡后，使用弹性网（Elastic Net， EN）进行特征选择生成EN分数，随机森林（Random Forest， RF）生成RF分数。这些数据，以及从人口统计学和血液学生物标志物中获得的两个基于svm的评分，被合并成一个集成ERSS （EN-RF-SVM-SVM）模型。采用ROC分析、校正和决策曲线分析来评估模型的性能。结果与单序列、多序列MRI集成模型和LR模型相比，ERSS模型具有更好的预测性能。在训练集和验证集上，ERSS模型的auc分别为0.957和0.968。校正曲线显示预测结果与观测结果非常吻合。DCA表明，与其他模型相比，ERSS模型在广泛的阈值概率范围内提供了最高的净临床效益。结论ERSS多模态集成学习模型为鼻咽癌患者RTLI的早期预测提供了一个高度准确且具有临床意义的工具。通过整合多序列MRI放射组学、血液学生物标志物和临床因素，ERSS模型可以实现个体化风险评估，并有助于优化放疗计划和随访策略。

{"title":"Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma","authors":"Meng Zhang , Jian Song , Yiming Yuan , Xiujuan Cao","doi":"10.1016/j.oraloncology.2025.107841","DOIUrl":"10.1016/j.oraloncology.2025.107841","url":null,"abstract":"<div><h3>Purpose</h3><div>To develop and validate a multimodal ensemble machine learning model integrating multi-sequence magnetic resonance imaging (MRI) radiomics, clinical characteristics, and hematological biomarkers for early prediction of Radiation-induced temporal lobe injury (RTLI) in Nasopharyngeal carcinoma (NPC) patients before radiotherapy.</div></div><div><h3>Methods</h3><div>A total of 161 NPC patients treated with intensity-modulated radiation therapy (IMRT) were retrospectively analyzed and randomly assigned to training (n = 113) and validation (n = 48) sets in a 7:3 ratio. Radiomic features were extracted from pretreatment T1WI, CE-T1WI, T2WI, and DWI, with features showing ICC > 0.75 retained. After SMOTE balancing, Elastic Net (EN) was used for feature selection to generate EN-scores, and Random Forest (RF) produced RF-scores. These, together with two SVM-based scores obtained from demographic and hematological biomarkers, were combined into an ensemble ERSS (EN–RF–SVM–SVM) model. Model performance was evaluated using ROC analysis, calibration, and decision curve analysis.</div></div><div><h3>Results</h3><div>The ERSS model demonstrated superior predictive performance compared with single-sequence, multi-sequence MRI integration models and LR model. The AUCs of the ERSS model were 0.957 in the training set and 0.968 in the validation set. Calibration curves showed excellent agreement between predicted and observed outcomes. DCA indicated that the ERSS model provided the highest net clinical benefit across a wide range of threshold probabilities compared with other models.</div></div><div><h3>Conclusion</h3><div>The ERSS multimodal ensemble learning model provides a highly accurate and clinically meaningful tool for early prediction of RTLI in NPC patients. By integrating multi-sequence MRI radiomics, hematological biomarkers, and clinical factors, the ERSS model enables individualized risk assessment and may assist in optimizing radiotherapy planning and follow-up strategies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107841"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145841965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial 接受新辅助免疫化疗的头颈部鳞状细胞癌患者的运动和生活质量：一项随机、开放标记的II期试验

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2025-12-31 DOI: 10.1016/j.oraloncology.2025.107844

Guoming Xiao , Li Ning , Lihui Chen , Shu Zhang , Yingle Chen , Yanfeng Chen

Background

Head and neck squamous cell carcinoma (HNSCC) significantly impairs patients’ quality of life (QoL). While neoadjuvant immuno-chemotherapy offers potential survival benefits, it is associated with substantial treatment-related toxicities, including fatigue, sleep disturbances, and functional decline. Exercise therapy has shown promise in improving QoL in other cancers, but its role in HNSCC patients receiving neoadjuvant therapy remains underexplored.

Methods

This single-center, open-label, randomized phase II trial enrolled 114 HNSCC patients undergoing neoadjuvant immuno-chemotherapy. Participants were randomized 1:1 to an exercise group (personalized breathing and aerobic exercise program) or a control group (routine care). Outcomes were assessed using the BFI-C, EORTC QLQ-C30, QLQ-H&N35, and PSQI at baseline, after 2 cycles, and after 3 cycles of therapy.

Results

The exercise group demonstrated significantly lower fatigue scores (BFI) after 2 and 3 cycles compared to controls (P < 0.05). Sleep quality (PSQI) improved significantly in the exercise group and worsened in the control group. The exercise group also showed better outcomes in physical functioning, fatigue and insomnia.

Conclusion

Exercise therapy is feasible and effective in reducing fatigue and improving sleep quality in HNSCC patients receiving neoadjuvant immuno-chemotherapy. Early integration of exercise may mitigate treatment-related symptoms and improve tolerance and overall QoL.

背景头颈部鳞状细胞癌（HNSCC）显著降低患者的生活质量（QoL）。虽然新辅助免疫化疗提供了潜在的生存益处，但它与大量治疗相关的毒性相关，包括疲劳、睡眠障碍和功能下降。运动疗法已显示出改善其他癌症患者生活质量的希望，但其在接受新辅助治疗的HNSCC患者中的作用仍未得到充分探讨。方法：该单中心、开放标签、随机II期试验纳入114例接受新辅助免疫化疗的HNSCC患者。参与者按1:1随机分为运动组（个性化呼吸和有氧运动计划）或对照组（常规护理）。采用基线时、治疗2个周期后和治疗3个周期后的BFI-C、EORTC QLQ-C30、qlq - hn35和PSQI进行结果评估。结果运动组在2、3个周期后的疲劳评分（BFI）明显低于对照组（P < 0.05）。睡眠质量（PSQI）在运动组显著改善，而在对照组恶化。锻炼组在身体机能、疲劳和失眠方面也表现出更好的结果。结论运动疗法对HNSCC新辅助免疫化疗患者减轻疲劳、改善睡眠质量是可行和有效的。早期整合运动可以减轻治疗相关症状，提高耐受性和总体生活质量。

{"title":"Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial","authors":"Guoming Xiao , Li Ning , Lihui Chen , Shu Zhang , Yingle Chen , Yanfeng Chen","doi":"10.1016/j.oraloncology.2025.107844","DOIUrl":"10.1016/j.oraloncology.2025.107844","url":null,"abstract":"<div><h3>Background</h3><div>Head and neck squamous cell carcinoma (HNSCC) significantly impairs patients’ quality of life (QoL). While neoadjuvant immuno-chemotherapy offers potential survival benefits, it is associated with substantial treatment-related toxicities, including fatigue, sleep disturbances, and functional decline. Exercise therapy has shown promise in improving QoL in other cancers, but its role in HNSCC patients receiving neoadjuvant therapy remains underexplored.</div></div><div><h3>Methods</h3><div>This single-center, open-label, randomized phase II trial enrolled 114 HNSCC patients undergoing neoadjuvant immuno-chemotherapy. Participants were randomized 1:1 to an exercise group (personalized breathing and aerobic exercise program) or a control group (routine care). Outcomes were assessed using the BFI-C, EORTC QLQ-C30, QLQ-H&N35, and PSQI at baseline, after 2 cycles, and after 3 cycles of therapy.</div></div><div><h3>Results</h3><div>The exercise group demonstrated significantly lower fatigue scores (BFI) after 2 and 3 cycles compared to controls (P < 0.05). Sleep quality (PSQI) improved significantly in the exercise group and worsened in the control group. The exercise group also showed better outcomes in physical functioning, fatigue and insomnia.</div></div><div><h3>Conclusion</h3><div>Exercise therapy is feasible and effective in reducing fatigue and improving sleep quality in HNSCC patients receiving neoadjuvant immuno-chemotherapy. Early integration of exercise may mitigate treatment-related symptoms and improve tolerance and overall QoL.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107844"},"PeriodicalIF":3.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145885901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative immunotherapy for head and neck cancer: from early successes to clinical challenges in relapsed and/or metastatic disease 头颈癌围手术期免疫治疗：从早期成功到复发和/或转移性疾病的临床挑战

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-02-01 Epub Date: 2026-01-15 DOI: 10.1016/j.oraloncology.2026.107853

Francesca Carosi , Sara Demurtas , Antonio Ciarfella , Ester Orlandi , Laura D. Locati

引用次数: 0